Clinical Trial

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II pilot, single arm, open label study designed to assess the efficacy, safety, and feasibility of MRD adapted duration of BR for untreated or R/R iNHL.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-08-13; most recent amendment 2025-01-03.
Trial Details
NCT Number NCT06557330
Lead Sponsor Fox Chase Cancer Center
Collaborators: Adaptive Biotechnologies
Conditions Lymphoma, Indolent Non-hodgkin Lymphoma
Enrollment 24 participants
Start Date 2025-06
Primary Completion 2027-09-29 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-06